Life Systems Corp (LSYC) 0.1000 $LSYC Type 2 Di
Post# of 273333
Posted On: 09/16/2016 1:11:17 AM
Life Systems Corp (LSYC) 0.1000 $LSYC
Type 2 Diabetes (T2D) - Pipeline Analysis 2014-2021
M2 - Wed Jun 10, 4:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p6rghv/type_2_diabetes) has announced the addition of the "Type 2 Diabetes (T2D) - Pipeline Analysis" report to their offering. The global Type 2 Diabetes (T2D) market is estimated to be $31.3 billion in 2014 and is expected to grow at a CAGR of mid-range single digit from 2015 to 2021 to reach $46.7 billion by 2021 Type 2 Diabetes (T2D) Pipeline Analysis gives comprehensive insight on the various drugs being developed for the treatment of T2D. The report covers all the drugs being developed in various phases (Discovery, Preclinical, Clinical & Marketing). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, monoclonal antibodies, stem cell therapies, Gene therapies, Recombinant proteins and RNA-based therapeutics, but excludes symptom relief drugs, generic combinations. The report also covers some of the hot targets in research for T2D treatments and disease progression biomarkers. This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Type 2 Diabetes (T2D) Drug market. The report also provide strategic insights on medicines that are likely to have an impact on T2D treatment space and potentially alter standards of care in T2D in the foreseeable future. Current therapies are focused on the treatment of hyperglycemia than on pancreatic Beta cell dysfunction and they lose efficacy over time as both endogenous insulin secretion and insulin sensitivity decrease. There is a need for type 2 diabetes therapies that act in concert with available agents to provide adequate glycemic control without causing hypoglycemia and weight gain, which are associated with increase in cardiovascular risk. Hence, it provides a tremendous opportunity for upcoming therapies specific to T2D such as MAbs, stem cell-based, gene therapies and RNA-based therapies. These modalities may provide beta-cell protection, regeneration, mass increase with additional benefits of weight loss, triglyceride lowering and kidney protection. Key Topics Covered: 1. Report Description 2. Introduction 3. Hot Targets, Mechanisms & Therapies 4. Market Data 5. Pipeline Analysis 6. Monoclonal ABs 7. Stemcell Therapy 8. Rna Based Therapeutics 9. Genetherapy 10. Recombinant Fusion Proteins 11. Drug Analysis Based On Mechanism 12. Major Players - Addex Therapeutics - Amgen - Astrazeneca - Boehringer Ingelheim - Connexios Life Systems - Eli & Lilly - Ember Therapeutics - Glaxosmithkline - Johnson & Johnson - Merck & Co - Mesoblast Biopharma Ltd - Poxel Sa - Takeda Pharmaceuticals - Xoma Corporation For more information visit http://www.researchandmarkets.com/research/p6...2_diabetes
JNJ: 118.63 (+0.77), MRK: 62.38 (+1.03), AMGN: 172.64 (+2.50)
Type 2 Diabetes (T2D) - Pipeline Analysis 2014-2021
M2 - Wed Jun 10, 4:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p6rghv/type_2_diabetes) has announced the addition of the "Type 2 Diabetes (T2D) - Pipeline Analysis" report to their offering. The global Type 2 Diabetes (T2D) market is estimated to be $31.3 billion in 2014 and is expected to grow at a CAGR of mid-range single digit from 2015 to 2021 to reach $46.7 billion by 2021 Type 2 Diabetes (T2D) Pipeline Analysis gives comprehensive insight on the various drugs being developed for the treatment of T2D. The report covers all the drugs being developed in various phases (Discovery, Preclinical, Clinical & Marketing). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, monoclonal antibodies, stem cell therapies, Gene therapies, Recombinant proteins and RNA-based therapeutics, but excludes symptom relief drugs, generic combinations. The report also covers some of the hot targets in research for T2D treatments and disease progression biomarkers. This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Type 2 Diabetes (T2D) Drug market. The report also provide strategic insights on medicines that are likely to have an impact on T2D treatment space and potentially alter standards of care in T2D in the foreseeable future. Current therapies are focused on the treatment of hyperglycemia than on pancreatic Beta cell dysfunction and they lose efficacy over time as both endogenous insulin secretion and insulin sensitivity decrease. There is a need for type 2 diabetes therapies that act in concert with available agents to provide adequate glycemic control without causing hypoglycemia and weight gain, which are associated with increase in cardiovascular risk. Hence, it provides a tremendous opportunity for upcoming therapies specific to T2D such as MAbs, stem cell-based, gene therapies and RNA-based therapies. These modalities may provide beta-cell protection, regeneration, mass increase with additional benefits of weight loss, triglyceride lowering and kidney protection. Key Topics Covered: 1. Report Description 2. Introduction 3. Hot Targets, Mechanisms & Therapies 4. Market Data 5. Pipeline Analysis 6. Monoclonal ABs 7. Stemcell Therapy 8. Rna Based Therapeutics 9. Genetherapy 10. Recombinant Fusion Proteins 11. Drug Analysis Based On Mechanism 12. Major Players - Addex Therapeutics - Amgen - Astrazeneca - Boehringer Ingelheim - Connexios Life Systems - Eli & Lilly - Ember Therapeutics - Glaxosmithkline - Johnson & Johnson - Merck & Co - Mesoblast Biopharma Ltd - Poxel Sa - Takeda Pharmaceuticals - Xoma Corporation For more information visit http://www.researchandmarkets.com/research/p6...2_diabetes
JNJ: 118.63 (+0.77), MRK: 62.38 (+1.03), AMGN: 172.64 (+2.50)
(0)
(0)